Redeye provides an in-depth take on AroCell’s Q1 report. Again, we emphasise that the company is trading at undemanding sales multiples, while enjoying solid sales growth with a controlled cost and cush burn, leaving a robust cash position – suitable for an eventual complementary acquisition of a product, in line with its proposed strategic overview.
LÄS MER
